Supplementary Table 1, Figures 1 - 3 from Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

Autor: Clinton F. Stewart, Burgess B. Freeman, Stacy L. Throm, K. Elaine Harstead, David M. Loeb, Jennifer Reikes Willert, Bhaskar Rao, Michael Neel, Victor M. Santana, Jianrong Wu, Shenghua Mao, Najat C. Daw, Fariba Navid, David C. Turner
Rok vydání: 2023
Popis: PDF file - 200K, Supplementary Table 1. Comparison of predictive performance for model parameterizations A, (B), and C (with IBW covariate) Supplemental Figure 1. The base structural bevacizumab model consisted of a two compartment model parameterized in terms of clearance from the central compartment and intercompartmental transfer to and from central and peripheral compartments. Supplemental Figure 2. Observed concentration-time data (filled diamonds) with simulations from individual posthoc parameter estimates (dashed lines; ~2 hrs step size) indicate that bevacizumab exhibits bi-exponential decay with a relatively rapid alpha phase and a prolonged beta terminal phase. Supplemental Figure 3. Visual predictive check of observed and model-predicted serum bevacizumab concentrations following 15 mg/kg dosing over a course of three occasions. The shaded region represents the 95% confidence interval of the Monte Carlo model simulations.
Databáze: OpenAIRE